DocGo (DCGO) customer relationships — who pays, who matters, and where the risk concentrates

DocGo monetizes by selling mobile healthcare and non-emergency medical transportation services to hospitals, payors and government entities, billing on a usage-based basis for trips and on contract rates for onsite/mobile clinics and managed services. The company combines proprietary dispatch software, dedicated vehicle fleets and staffed crews to generate recurring revenue from long-term contracts with health systems and sizeable government work, while pursuing diversification into retail pilots and international markets. For investors, the fundamental trade-off is rapid top-line scale driven by large, visible contracts against concentrated counterparty exposure and reimbursement/government risk. Learn more at https://nullexposure.com/.

How DocGo's operating model converts contracts into cash

DocGo operates as a service provider and seller of clinical and transport solutions, generating most revenue from Mobile Health Services and Transportation Services. Contracts are predominantly usage-based for transportation — customers pay per completed trip — which makes revenue highly volume-sensitive to utilization patterns and seasonality. The company's revenue mix is also skewed toward government payors, which historically accounted for the majority of revenues, and it operates in both North America and the U.K., providing a cross-border growth vector.

• Contracting posture: predominantly usage-based for transportation, with longer-term management agreements for transfer centers and clinic programs that provide visibility into volumes.
• Concentration: the company reported two customers that together accounted for a material share of revenue (one ~38%, another ~28% in 2024), creating counterparty risk that affects receivables and liquidity.
• Criticality and maturity: management describes the transportation business as a foundational asset expected to exceed $200 million in revenue in 2025 with a pathway to improved adjusted EBITDA margins as scale and staffing efficiency are realized.
• Geographic footprint: primarily North America with meaningful operations in the U.K., exposing DocGo to both U.S. government contracting dynamics and U.K. public health procurement.

If you want a concise, professional breakdown of counterparty risk and revenue drivers, visit https://nullexposure.com/ for structured exposure analysis.

Customer roster: the relationships that drive credibility and risk

Jefferson Health

DocGo lists Jefferson Health among its large health system customers that use its total transportation solution, which combines software, ambulances, EMS crews and staffing to operate transfer center functions; management highlighted Jefferson as part of the roster driving record volumes in Q3 2025. According to the Q3 2025 earnings call, this vertical is a core source of scale and margin expansion.

Mount Sinai

Mount Sinai appears on DocGo’s cited roster of long-term contracts that drove record volumes in the transportation business in Q3 2025, reflecting strong visibility from major health systems and reinforcing DocGo’s penetration into large urban hospital networks (Q3 2025 earnings call).

New York City Health and Hospitals

New York City Health and Hospitals is named as a long-term transportation customer in the Q3 2025 earnings call; the relationship illustrates municipal-scale engagements that produce steady trip volumes and stable billing flows (Q3 2025 earnings call).

NHS (United Kingdom)

DocGo identifies the U.K. National Health Service among its notable customers, supporting its international footprint and validating its transportation model outside the U.S.; the company cites the NHS as part of the roster behind record volumes in Q3 2025 (Q3 2025 earnings call).

New York City (municipal emergency contract)

A New York Post investigation noted DocGo received an emergency contract in May 2023 tied to migrant shelter services worth approximately $432 million, illustrating the company’s ability to win large-scale municipal contracts but also the reputational and political scrutiny that can accompany such awards (New York Post, Oct 2024).

Dollar General (retail pilot)

DocGo and Dollar General ran a pilot placing mobile clinics in store parking lots in Tennessee; media reports described the initiative as a test of retail-healthcare delivery and later noted the pilot’s conclusion, signaling a pursuit of retail channels but limited near-term revenue evidence from that program (MedCityNews, Jun 2024; Modern Healthcare, 2024).

HCA TriStar

HCA TriStar is included among DocGo’s long-term transportation customers cited in the company’s Q3 2025 remarks, indicating penetration into large hospital systems within HCA’s regional networks and contributing to transportation volume growth (Q3 2025 earnings call).

UnitedHealthcare

A public commentary in FY2025 indicated UnitedHealthcare did not have a contract with DocGo in New York, underscoring that national payor partnerships are not uniform across regions and that payor relationships require localized negotiation and credentialing (ClassActionLawyers.com commentary, FY2025).

What this roster signals for investors

The customer list contains large, creditworthy health systems and government entities, which drives scale and validate the product offering, but the roster also encodes key risks:

• High counterparty concentration creates single-customer sensitivity: two customers accounted for ~66% of 2024 revenues between them, a material lever on cash flow and receivables.
• Government exposure is significant: government work represented a substantial portion of revenues in recent years, so procurement cycles and political scrutiny (e.g., the NYC migrant contract coverage) are direct risk vectors.
• Usage-based billing for transportation means revenue is volume-driven, so operational execution and staffing are direct margin drivers; management targets an adjusted EBITDA contribution margin of roughly 12% for the scaled transportation business over the next 2–3 years (Q3 2025 earnings call).
• Geographic diversification to the U.K. reduces single-market risk but introduces public-sector procurement complexity and currency/regulatory considerations.

For investors focused on counterparty and operational risk, monitor contract renewals, receivable aging from top customers, and disclosure around the two largest customers that accounted for the bulk of 2024 revenue. If you want a full counterparty exposure dossier, see https://nullexposure.com/.

Positioning and near-term monitoring checklist

Investors should treat DocGo as a growth company with concentrated customer risk and a path to margin improvement via scale in transportation. Key monitoring items:

• Renewals and bid outcomes for large municipal and health system contracts.
• Receivables tied to the two largest customers and any signs of collection stress.
• Utilization trends in transportation trips and staffing efficiency that support the 12% adjusted EBITDA target disclosed for the segment.
• Public-policy and reputational developments tied to large government contracts, particularly municipal engagements.

Actionable stance: weigh DocGo’s durable revenue opportunities from health systems and government contracts against the fragility introduced by customer concentration and political scrutiny; allocate accordingly and require evidence of diversified revenue before increasing exposure.

For detailed counterparty scoring and alerts on material customer events, visit https://nullexposure.com/ — the site aggregates the signals driving valuation and operational risk for healthcare services operators.

— End of analysis.